The present study aimed to evaluate the efficacy of cabazitaxel in Japanese patients affected by metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. In this retrospective study, 41 patients with mCRPC treated with cabazitaxel at Keio University Hospital were retrospectively reviewed. Cabazitaxel at a dose of 20-25 mg/m² was administered every 3 or 4 weeks. Clinicopathological factors and laboratory data were collected to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). An upfront dose-reduction was required in 52.5% of patients due to their reduced general condition or advanced age. Prophylactic G-CSF was prescribed to all the patients. Grade ≥3 neutropenia and febrile neutropenia occurred in 21 patients (53.6%) and 3 patients (6.8%), respectively. Treatment was generally well tolerated, with a median of 5 cycles (range 1-17). Median PFS and OS from the start of cabazitaxel treatment were 4.4 and 15.0 months (95% CI 8.9-21.2), respectively. Waterfall plot analysis revealed that a prostate-specific antigen (PSA) decline >50% was noticed in n = 11 patients receiving cabazitaxel (26.8%). Univariate analysis revealed that poor performance status, PSA ≥100 ng/mL prior to cabazitaxel treatment, visceral metastasis, absence of grade 3/4 neutropenia during cabazitaxel therapy and neutrophil-lymphocyte ratio were significantly associated with shorter overall survival. Multivariate analysis revealed that poor performance status, visceral metastasis, and the absence of grade 3/4 neutropenia during cabazitaxel therapy were the independent prognostic indicators for OS. The practical implication of our results might be to tailor cabazitaxel dosing on the basis of its hematological effects. In a phase III TROPIC study, performed in patients with mCRPC progressing during or after docetaxel, cabazitaxel provided an overall survival (OS) benefit.
| INTRODUCTION
Cabazitaxel is a next-generation taxane, indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. 1, 2 In a phase III TROPIC study, performed in patients with mCRPC progressing during or after docetaxel, cabazitaxel provided an overall survival (OS) benefit.
1,2 As a result, cabazitaxel was approved worldwide for the treatment of patients with mCRPC previously treated with a docetaxel-containing regimen. [3] [4] [5] In a phase I, open-label, dose-escalation study of cabazitaxel in patients with mCRPC in Japan (NCT01324583), the safety,
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. tolerability data and antitumor activity in Japanese patients were found to be comparable to the results of previous studies in Caucasian patients, although the incidences of neutropenia and febrile neutropenia were high in a Japanese study. 6, 7 In Japan, cabazitaxel was approved in September 2014 for patients with metastatic docetaxel-resistant castration-resistant prostate cancer.
In Asian populations, including Japanese populations, the efficacy and the prognostic indicators of cabazitaxel remain unclear.
The aim of the present study was to evaluate the efficacy and prognostic factors of cabazitaxel in combination with prednisone treatment in Japanese patients with mCRPC previously treated with docetaxel. analysis were included in the multivariable analysis. Categorized variables were assessed in multivariate models using Cox proportional hazard regression models with a stepwise forward selection method.
| MATERIALS AND METHODS
For all statistical analyses, tests were 2-sided and P < .05 was considered to indicate statistical significance. All statistical analyses were performed using the Statistical Package of the Social Sciences, version 24.0 (SPSS, Chicago, IL, USA).
3 | RESULTS
| Patient characteristics
All patients were Japanese and had received at least 1 prior docetaxel-containing regimen ( Prostate-specific antigen decline >50% on cabazitaxel showed a statistically significant prolonged PFS (9.5 vs 4.2 months, P = .049).
However, a PSA decline >50% on cabazitaxel did not exhibit a prolonged OS (12.5 vs 15.1 months, P = .134). When the cut-off level of PSA decline was decreased, statistical significance was reached for the cohort with a PSA decline of at least 25% for PFS (7.4 vs 3.7 months, P = .006) and OS (16.2 vs 9.1 months, P = .037).
Univariate analysis revealed that PSA ≥100 ng/mL prior to cabazitaxel treatment, Hb <11 mg/dL, higher alkaline phosphatase (ALP), upfront dose-reduction of cabazitaxel and the absence of grade 3/4 neutropenia during cabazitaxel therapy were significantly associated with shorter PFS (Table 3 ). Multivariate analysis revealed that upfront dose reduction of cabazitaxel (HR = .4; CI 0.18-0.91, P = .028) and higher ALP (HR = 3.91; CI 1.52-10.03, P = .005) were independent prognostic indicators for PFS.
In relation to OS, from the univariate analysis, poor PS, PSA ≥100 ng/mL prior to cabazitaxel treatment, visceral metastasis, the absence of grade 3/4 neutropenia during cabazitaxel therapy ( Figure 2B ) and neutrophil-lymphocyte ratio were significantly asso- (Table 4 ).
| DISCUSSION
Cabazitaxel was the first agent demonstrating a survival benefit in men with mCRPC progressing during or after docetaxel. Grade ≥3 neutropenia and febrile neutropenia occurred in 21 patients (53.6%) and 3 (6.8%) patients, respectively, which is believed to be an improvement compared to the phase I cabazitaxel study in Japanese patients.
In many solid tumor types and hematological malignancies, chemotherapy-induced neutropenia is associated with an improved OS in many solid tumors. [13] [14] [15] In the context of mCRPC, a retrospective analysis in patients treated with docetaxel and a post-hoc analysis of the TROPIC trial demonstrated that the occurrence of grade 3/4 neutropenia with cabazitaxel is associated with prolonged OS. 16, 17 In this study, multivariate analysis revealed that the absence of grade 3/4 neutropenia during cabazitaxel therapy was an independent prognostic indicator for OS. The absence of grade 3/4 neutropenia could suggest insufficient drug exposure in some patients.
In relation to drug exposure, we evaluated the correlation of the relative dose intensity (RDI) and grade 3/4 neutropenia. The median RDI of the patients with grade 1/2 or grade 3/4 neutropenia was F I G U R E 2 A, Waterfall plot of maximum percentage change in prostate-specific antigen (PSA) level from baseline in the grade 3/4 (G3/4) specified population (n = 41). Black bar indicates the patients with G3/4 neutropenia. B, Kaplan-Meier for time to overall survival in the grade 3/4 (G3/4) specified population (n = 41) In the PSA era, PSA played a crucial role in prostate cancer diagnosis, the definition of CRPC, and indicating the extent of disease progression. In this study, univariate analysis revealed that the subgroup analysis in the TAX327 trial demonstrated that PSA was not a prognostic factor and that PSA does not necessarily follow the exacerbation of the disease in the metastatic stage, suggesting that only relying on PSA changes in mCRPC patients may be misleading to clinicians with respect to making critical decisions with regard to whether to continue or change the current treatment. 19, 20 In our study, a PSA decline >50% on cabazitaxel did not show a prolonged OS; however, statistical significance was reached for the cohort with a PSA decline of at least 25% for PFS (7.4 vs 3.7 months, P = .006) and OS (16.2 vs 9.1 months, P = .037). In combination with imaging modality, a PSA decline >25% may have practical implications for decision-making, although multivariate analysis did not reveal the significance of a PSA decline >25% as a prognostic indicator.
We acknowledge that there are several limitations in our study.
The study design was retrospective and involved a relatively small population. Therefore, a prospective study based on our study results is warranted to prove whether these predictive factors would be useful in an actual clinical setting.
In conclusion, we have identified PS and the absence of grade 3/ 4 neutropenia as potential predictors of prognostic indicators during cabazitaxel therapy in Japanese CRPC patients.
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